DAVID ALAN LEWIS, MD
Medical Practice in Madison, WI
License number
Wisconsin 54554-20
Category
Medical Practice
Type
Ophthalmology
Address
Address
600 F4/349, Madison, WI 53792
Phone
(405) 473-6491
Professional information
Dr. David A Lewis, Madison WI - MD (Doctor of Medicine)
Specialties:
Ophthalmology
Age:
47
Address:
600 Highland Ave STE F4349, Madison 53792
(405) 473-6491 (Phone), (608) 263-1466 (Fax)
TEXAS TECH UNIVERSITY
3601 4Th St STE 7217, Lubbock 79430
(806) 743-2020 (Phone), (806) 743-1782 (Fax)
Madison Office
600 Highland Ave STE H4831, Madison 53792
(608) 263-6400 (Phone), (608) 890-7127 (Fax)
(405) 473-6491 (Phone), (608) 263-1466 (Fax)
TEXAS TECH UNIVERSITY
3601 4Th St STE 7217, Lubbock 79430
(806) 743-2020 (Phone), (806) 743-1782 (Fax)
Madison Office
600 Highland Ave STE H4831, Madison 53792
(608) 263-6400 (Phone), (608) 890-7127 (Fax)
Certifications:
Ophthalmology, 2012
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Oklahoma / Health Sciences Center
Graduated: 2006
University of Oklahoma / Health Sciences Center
Graduated: 2006
Compositions For Targeted Delivery Of Sirna
US Patent:
2013024, Sep 19, 2013
Filed:
Sep 14, 2012
Appl. No.:
13/615938
Inventors:
David B. Rozema - Middleton WI, US
David L. Lewis - Madison WI, US
Darren H. Wakefield - Fitchburg WI, US
Torsten Hoffmann - Weil am Rhein, DE
Eric A. Kitas - Baselland, CH
Peter Mohr - Basel, CH
Philipp Hadwiger - Kulmbach, DE
Wilma Thuer - Kulmbach, DE
Linda Valis - Bamberg, DE
David L. Lewis - Madison WI, US
Darren H. Wakefield - Fitchburg WI, US
Torsten Hoffmann - Weil am Rhein, DE
Eric A. Kitas - Baselland, CH
Peter Mohr - Basel, CH
Philipp Hadwiger - Kulmbach, DE
Wilma Thuer - Kulmbach, DE
Linda Valis - Bamberg, DE
Assignee:
ARROWHEAD MADISON INC. - Madison WI
International Classification:
A61K 47/32, A61K 47/48
US Classification:
514 44 A
Abstract:
The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.
Compositions And Processes Using Sirna, Amphipathic Compounds And Polycations
US Patent:
2004013, Jul 15, 2004
Filed:
Jan 15, 2003
Appl. No.:
10/345021
Inventors:
David Lewis - Madison WI, US
Hans Herweijer - Madison WI, US
Sean Monahan - Madison WI, US
Jon Wolff - Madison WI, US
James Hagstrom - Middleton WI, US
Aaron Loomis - Prairie du Sac WI, US
Hans Herweijer - Madison WI, US
Sean Monahan - Madison WI, US
Jon Wolff - Madison WI, US
James Hagstrom - Middleton WI, US
Aaron Loomis - Prairie du Sac WI, US
International Classification:
A61K048/00, A61K009/14
US Classification:
424/486000, 514/044000
Abstract:
Described is a composition with low toxicity comprising an amphipathic compound and a polycation, useful for delivering siRNA to a cell. The composition may be used in the process of delivering a siRNA to an animal cell, or more particularly a mammal cell, in a multi-well format.
Inhibition Of Rna Function By Delivery Of Inhibitors To Animal Cells
US Patent:
2003014, Jul 31, 2003
Filed:
Jul 1, 2002
Appl. No.:
10/186757
Inventors:
David Lewis - Madison WI, US
James Hagstrom - Madison WI, US
Hans Herweijer - Madison WI, US
Aaron Loomis - Prairie du Sac WI, US
Sean Monahan - Madison WI, US
Vladimir Trubetskoy - Madison WI, US
Jon Wolff - Madison WI, US
James Hagstrom - Madison WI, US
Hans Herweijer - Madison WI, US
Aaron Loomis - Prairie du Sac WI, US
Sean Monahan - Madison WI, US
Vladimir Trubetskoy - Madison WI, US
Jon Wolff - Madison WI, US
International Classification:
A61K048/00, C12N015/86
US Classification:
424/093200, 435/456000
Abstract:
Described is a process for delivering an inhibitor directed against an expressible nucleic acid sequence in a mammal to inhibit RNA function. An RNA function inhibiting sequence that is specific to the expressible nucleic acid sequence in the mammal is made and inserted into a blood vessel in the mammal. The inhibitor is delivered to a cell wherein expression of the nucleic acid sequence is inhibited.
Inhibition Of Gene Expression By Delivery Of Polynucleotides To Animal Cells In Vivo
US Patent:
2007012, Jun 7, 2007
Filed:
Jan 4, 2007
Appl. No.:
11/649502
Inventors:
David Lewis - Madison WI, US
Jon Wolff - Madison WI, US
Vladimir Budker - Middleton WI, US
Hans Herweijer - Brooklyn WI, US
James Hagstrom - Middleton WI, US
Jon Wolff - Madison WI, US
Vladimir Budker - Middleton WI, US
Hans Herweijer - Brooklyn WI, US
James Hagstrom - Middleton WI, US
International Classification:
A61K 48/00
US Classification:
424093200, 514044000
Abstract:
Described is a process for intravascular delivery of a polynucleotide to an extravascular cell of a mammal to inhibit gene expression. A polynucleotide containing sequence that is similar to a sequence in the gene to be expressed is made and inserted into a vessel in the mammal. The polynucleotide is delivered to a cell wherein expression of the gene is inhibited.
In Vivo Inhibition Of Hepatitis B Virus
US Patent:
2006006, Mar 23, 2006
Filed:
Sep 26, 2005
Appl. No.:
11/234947
Inventors:
David Lewis - Madison WI, US
Jon Wolff - Madison WI, US
Hans Herweijer - Brooklyn WI, US
James Hagstrom - Middleton WI, US
Aaron Loomis - Prairie du Sac WI, US
Jon Wolff - Madison WI, US
Hans Herweijer - Brooklyn WI, US
James Hagstrom - Middleton WI, US
Aaron Loomis - Prairie du Sac WI, US
International Classification:
A61K 48/00
US Classification:
514044000
Abstract:
A process is provided to deliver polynucleotide-based gene expression inhibitors to cells in a mammal in vivo for the purpose of inhibiting gene expression in the cells. Inhibition is sequence-specific and relies on sequence similarity to of the polynucleotide-based gene expression inhibitor and the target nucleic acid molecule. Delivery of the polynucleotide-based gene expression inhibitor can enhance the efficacy of co-delivered small molecule drugs.
Inhibition Of Gene Function By Delivery Of Polynucleotide-Based Gene Expression Inhibitors To Mammalian Cells In Vivo
US Patent:
2005003, Feb 17, 2005
Filed:
Jun 23, 2004
Appl. No.:
10/874528
Inventors:
David Lewis - Madison WI, US
Jon Wolff - Madison WI, US
Hans Herweijer - Madison WI, US
James Hagstrom - Middleton WI, US
Aaron Loomis - Prairie du Sac WI, US
Andrew Spencer - Madison WI, US
Jon Wolff - Madison WI, US
Hans Herweijer - Madison WI, US
James Hagstrom - Middleton WI, US
Aaron Loomis - Prairie du Sac WI, US
Andrew Spencer - Madison WI, US
International Classification:
A61K048/00
US Classification:
514044000
Abstract:
A process is provided to deliver polynucleotide-based gene expression inhibitors to cells in a mammal in vivo for the purpose of inhibiting gene expression in the cells. Inhibition is sequence-specific and relies on sequence similaroty of the polynucleotide-based gene expression inhibitor and the target nucleic acid molecule. Delivery of the polynucleotide-based gene expression inhibitor can enhance the efficacy of co-delivered small molecule drugs.
Compositions And Processes For Inhibiting Gene Expression Using Polynucleotides
US Patent:
2003022, Dec 4, 2003
Filed:
May 28, 2003
Appl. No.:
10/446252
Inventors:
David Lewis - Madison WI, US
David Rozema - Madison WI, US
Darren Wakefield - Madison WI, US
Hans Herweijer - Madison WI, US
Jon Wolff - Madison WI, US
James Hagstrom - Middleton WI, US
David Rozema - Madison WI, US
Darren Wakefield - Madison WI, US
Hans Herweijer - Madison WI, US
Jon Wolff - Madison WI, US
James Hagstrom - Middleton WI, US
International Classification:
A61K038/16, A61K048/00, A61K009/14, C12N015/85
US Classification:
424/486000, 435/455000, 514/012000, 514/081000
Abstract:
Compositions are provided for delivery of polynucleotides to cells for the purpose of inhibiting gene expression. Antisense polynucleotide-containing complexes are described. The salt and serum stability and small size of the complexes permits delivery to cells in vitro and in vivo.
Peptide-Based In Vivo Sirna Delivery System
US Patent:
2013028, Oct 24, 2013
Filed:
Jun 25, 2013
Appl. No.:
13/926380
Inventors:
David L Lewis - Madison WI, US
Darren Wakefield - Fitchburg WI, US
Eric Kitas - Aesch BL, CH
Philipp Hadwiger - Kulmbach, DE
Jon Wolff - Madison WI, US
Ingo Röhl - Memmelsdorf, DE
Peter Mohr - Basel, CH
Torsten Hoffmann - Weil am Rhein, DE
Kerstin Jahn-Hofmann - Neu-Isenburg, DE
Hans Martin Mueller - Munich, DE
Günther Ott - Bayreuth, DE
Andrei V Blokhin - Fitchburg WI, US
Jonathan D Benson - Stoughton WI, US
Jeffrey C Carlson - Madison WI, US
Darren Wakefield - Fitchburg WI, US
Eric Kitas - Aesch BL, CH
Philipp Hadwiger - Kulmbach, DE
Jon Wolff - Madison WI, US
Ingo Röhl - Memmelsdorf, DE
Peter Mohr - Basel, CH
Torsten Hoffmann - Weil am Rhein, DE
Kerstin Jahn-Hofmann - Neu-Isenburg, DE
Hans Martin Mueller - Munich, DE
Günther Ott - Bayreuth, DE
Andrei V Blokhin - Fitchburg WI, US
Jonathan D Benson - Stoughton WI, US
Jeffrey C Carlson - Madison WI, US
International Classification:
A61K 47/48
US Classification:
530322
Abstract:
The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.
Peptide-Based In Vivo Sirna Delivery System
US Patent:
8501930, Aug 6, 2013
Filed:
Dec 15, 2011
Appl. No.:
13/326433
Inventors:
David B. Rozema - Middleton WI, US
Darren H. Wakefield - Fitchburg WI, US
David L. Lewis - Madison WI, US
Jon A. Wolff - Madison WI, US
Andrei V. Blokhin - Fitchburg WI, US
Jonathan D. Benson - Stoughton WI, US
Jeffrey C. Carlson - Madison WI, US
Philipp Hadwiger - Kulmbach, DE
Eric A. Kitas - Aesch BL, CH
Torsten Hoffmann - Weil am Rhein, DE
Kerstin Jahn-Hofmann - Neu-Isenburg, DE
Peter Mohr - Basel, CH
Hans Martin Mueller - Munich, DE
Guenther Ott - Bayreuth, DE
Ingo Roehl - Memmelsdorf, DE
Darren H. Wakefield - Fitchburg WI, US
David L. Lewis - Madison WI, US
Jon A. Wolff - Madison WI, US
Andrei V. Blokhin - Fitchburg WI, US
Jonathan D. Benson - Stoughton WI, US
Jeffrey C. Carlson - Madison WI, US
Philipp Hadwiger - Kulmbach, DE
Eric A. Kitas - Aesch BL, CH
Torsten Hoffmann - Weil am Rhein, DE
Kerstin Jahn-Hofmann - Neu-Isenburg, DE
Peter Mohr - Basel, CH
Hans Martin Mueller - Munich, DE
Guenther Ott - Bayreuth, DE
Ingo Roehl - Memmelsdorf, DE
Assignee:
Arrowhead Madison Inc. - Madison WI
International Classification:
C07H 21/04, C07H 21/02, C07K 5/00
US Classification:
536 245, 536 231, 530300
Abstract:
The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.